PerspectiveType 1 Diabetes

Humanizing Animal Models: A Key to Autoimmune Diabetes Treatment

See allHide authors and affiliations

Science Translational Medicine  02 Feb 2011:
Vol. 3, Issue 68, pp. 68ps4
DOI: 10.1126/scitranslmed.3002102

You are currently viewing the abstract.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


Preclinical evaluation of antibody-based immunotherapies for the treatment of type 1 diabetes (T1D) in animal models is often hampered by the fact that the human antibody drug does not cross-react with its mouse counterpart. In this issue of Science Translational Medicine, researchers describe a new mouse model that expresses the human isoform of a molecule targeted by T1D antibody therapies that are currently being tested in clinical trials—the human epsilon chain of the CD3 complex expressed on T cells. Anti-CD3 is capable of reducing insulin needs in individuals with recently diagnosed T1D; however, the precise underlying mechanisms of action and the minimal effective dose have been difficult to define. The new humanized mouse model will be instrumental in optimizing anti-CD3–based therapies and accelerating their clinical realization.


  • Citation: D. Bresson, M. von Herrath, Humanizing Animal Models: A Key to Autoimmune Diabetes Treatment. Sci. Transl. Med. 3, 68ps4 (2011).

View Full Text

Stay Connected to Science Translational Medicine